ERBB2 and invasive breast carcinoma: Another agent in the resistance to which Hsp27 has been found implicated is trastuzumab, also known as herceptin, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), which is overexpressed in up to 30% of invasive breast cancer cases and also in some gastric cancer subtypes.